What is the detection process of Sidi's diagnosis of NGS?

Now with the development of global science and technology, the treatment in the field of anti-tumor is more diversified. For example, in the field of precision medicine, NGS (second generation sequencing) has become an indispensable auxiliary diagnostic tool on the road of anti-tumor treatment. The process is as follows:

For patients receiving NGS testing, only tissue samples and non-invasive ctDNA samples need to be provided. The testing process of NGS is very strict. From receiving samples to the final report, Sidi actually needs to go through 10 process: receiving samples, checking pathology, hemolysis and separation, nucleic acid extraction, library construction, automatic capture process, sequencing, analysis and annotation, review and sending reports.

After strict review, the final report is presented to doctors and patients in a rigorous and credible way, and the results can provide reference for clinicians' follow-up tumor treatment strategies.

According to official data, Sidi Diagnosis was spun off from Sidi Group, focusing on accurate diagnosis. At present, it has technical platforms including NGS (gene second generation sequencing technology), qPCR, foreign body nucleic acid/protein detection, artificial intelligence data analysis, and a number of third-party inspection institutions, with more than 200 R&D personnel.

At present, CCID Diagnostics has two business lines: third-party medical inspection services and IVD equipment and reagents, and has laid out a series of product research and development pipelines in the fields of tumor (from early diagnosis, accompanying diagnosis to dynamic monitoring) and microbial diagnosis.

Among them, in the field of early tumor diagnosis, Sidi diagnosis is based on an independent exosome marker development platform, and the developed ovarian cancer early diagnosis kit has entered the registered clinical trial.

In addition, in the field of tumor diagnosis and dynamic monitoring, Sidi completed a fully automatic data analysis system on 20 18. Subsequently, on 20 19, ANDiS400, which has the function of fully automatic preparation of closed gene library, was approved by the US Food and Drug Administration in China.

At present, Sidi Diagnostics has formed a series of R&D pipelines of fully automatic platform, and established corresponding development and registration pipelines of accompanying diagnosis and dynamic monitoring automation products. In the future, with the pipeline products coming on the market one after another, it will help to break through the bottleneck that NGS technology for tumor is too complicated to be scaled up in domestic hospitals.